vortioxetine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives 4806 508233-74-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vortioxetine-DL-lactate
  • vortioxetine DL-lactate
  • brintellix
  • Lu AA21004
  • vortioxetine
  • vortioxetine hydrobromide
A piperazine derivative that acts as a serotonin reuptake inhibitor, as a 5-HT3 receptor antagonist, and 5-HT1A receptor agonist. It is used for the treatment of anxiety and depression.
  • Molecular weight: 298.45
  • Formula: C18H22N2S
  • CLOGP: 4.92
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 15.27
  • ALOGS: -4.92
  • ROTB: 3

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 35.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 72 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 30, 2013 FDA TAKEDA PHARMS USA
Sept. 20, 2019 PMDA Takeda Pharmaceutical Company Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 929.88 39.67 397 2017 111792 2243879
Pruritus 562.09 39.67 214 2200 43126 2312545
Suicidal ideation 536.02 39.67 149 2265 10938 2344733
Vomiting 277.18 39.67 153 2261 71449 2284222
Anxiety 180.36 39.67 86 2328 29273 2326398
Depression 150.42 39.67 75 2339 28057 2327614
Rash 147.81 39.67 96 2318 59462 2296209
Feeling abnormal 138.32 39.67 67 2347 23514 2332157
Headache 137.55 39.67 103 2311 80076 2275595
Mania 136.67 39.67 37 2377 2403 2353268
Anger 131.02 39.67 36 2378 2471 2353200
Suicide attempt 124.42 39.67 50 2364 11232 2344439
Insomnia 115.28 39.67 61 2353 25726 2329945
Agitation 111.64 39.67 46 2368 11005 2344666
Dizziness 106.24 39.67 78 2336 58587 2297084
Serotonin syndrome 106.00 39.67 33 2381 3507 2352164
Irritability 105.12 39.67 38 2376 6389 2349282
Tremor 101.23 39.67 52 2362 20609 2335062
Constipation 96.13 39.67 51 2363 21578 2334093
No adverse event 93.96 39.67 39 2375 9489 2346182
Weight increased 91.80 39.67 50 2364 22287 2333384
Completed suicide 91.79 39.67 49 2365 20985 2334686
Abnormal dreams 82.41 39.67 25 2389 2433 2353238
Crying 79.44 39.67 28 2386 4368 2351303
Intentional overdose 77.98 39.67 36 2378 11285 2344386
Somnolence 76.05 39.67 45 2369 23440 2332231
Hyponatraemia 75.37 39.67 37 2377 13288 2342383
Nightmare 72.38 39.67 25 2389 3672 2351999
Wrong technique in product usage process 64.32 39.67 38 2376 19710 2335961
Diarrhoea 63.58 39.67 68 2346 83496 2272175
Vision blurred 60.64 39.67 33 2381 14635 2341036
Contusion 59.08 39.67 31 2383 12779 2342892
Drug ineffective 52.77 39.67 68 2346 101556 2254115
Urticaria 52.34 39.67 36 2378 24225 2331446
Energy increased 50.50 39.67 12 2402 457 2355214
Sexual dysfunction 49.11 39.67 11 2403 321 2355350
Off label use 47.47 39.67 55 2359 73543 2282128
Palpitations 46.68 39.67 29 2385 16427 2339244
Fatigue 45.90 39.67 58 2356 84815 2270856
Blood pressure increased 45.84 39.67 29 2385 16957 2338714
Hyperhidrosis 45.84 39.67 28 2386 15394 2340277
Product use in unapproved indication 45.72 39.67 25 2389 11175 2344496
Electrocardiogram QT prolonged 45.04 39.67 22 2392 7792 2347879
Vertigo 44.07 39.67 23 2391 9361 2346310
Drug abuse 44.05 39.67 25 2389 12001 2343670
Antipsychotic drug level above therapeutic 43.53 39.67 9 2405 178 2355493
Aggression 41.82 39.67 18 2396 4768 2350903
Overdose 41.64 39.67 29 2385 19878 2335793
Sopor 41.52 39.67 17 2397 3978 2351693

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 296.33 39.21 83 1013 8435 1737250
Completed suicide 267.09 39.21 89 1007 16223 1729462
Nausea 195.08 39.21 98 998 51098 1694587
Anxiety 159.02 39.21 60 1036 15467 1730218
Sexual dysfunction 101.96 39.21 26 1070 1797 1743888
Vomiting 101.65 39.21 58 1038 38257 1707428
Feeling abnormal 88.70 39.21 36 1060 11130 1734555
Suicide attempt 73.31 39.21 28 1068 7353 1738332
Drug ineffective 72.46 39.21 57 1039 63744 1681941
Agitation 65.67 39.21 29 1067 10997 1734688
Mania 61.17 39.21 18 1078 2115 1743570
Dizziness 60.12 39.21 40 1056 34321 1711364
Headache 57.69 39.21 39 1057 34337 1711348
Depression 57.10 39.21 30 1066 16639 1729046
Intentional overdose 51.58 39.21 22 1074 7648 1738037
Erectile dysfunction 44.37 39.21 17 1079 4480 1741205
Serotonin syndrome 44.31 39.21 15 1081 2773 1742912
Insomnia 41.15 39.21 24 1072 16252 1729433
Weight increased 40.43 39.21 21 1075 11336 1734349

Pharmacologic Action:

SourceCodeDescription
ATC N06AX26 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35941 serotonergic agonist
CHEBI has role CHEBI:48279 serotonergic antagonist
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D058831 Serotonin 5-HT3 Receptor Antagonists
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D017367 Serotonin Uptake Inhibitors
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.02 Basic
pKa2 1.85 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 8476279 Oct. 2, 2022 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 8476279 Oct. 2, 2022 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 8476279 Oct. 2, 2022 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 8476279 Oct. 2, 2022 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 7144884 June 17, 2026 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 7144884 June 17, 2026 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 7144884 June 17, 2026 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 7144884 June 17, 2026 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 8969355 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125908 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125909 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125910 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9227946 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9861630 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 8969355 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 9125908 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 9125909 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 9125910 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 9227946 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 9861630 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 8969355 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125908 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125909 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125910 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9227946 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9861630 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 8969355 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125908 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125909 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9125910 June 15, 2027 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9227946 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9861630 June 15, 2027 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9278096 March 21, 2032 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL 9278096 March 21, 2032 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9278096 March 21, 2032 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL 9278096 March 21, 2032 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL May 2, 2021 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL May 2, 2021 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL May 2, 2021 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL May 2, 2021 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL Oct. 19, 2021 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 DISCN TABLET ORAL Oct. 19, 2021 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
EQ 20MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL Oct. 19, 2021 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
EQ 5MG BASE TRINTELLIX TAKEDA PHARMS USA N204447 Sept. 30, 2013 RX TABLET ORAL Oct. 19, 2021 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 7.82 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.80 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7.72 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 1D GPCR ANTAGONIST Ki 7.27 DRUG LABEL DRUG LABEL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.48 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 3A Ion channel ANTAGONIST Ki 8.43 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Histamine H2 receptor GPCR Ki 6.74 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.74 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.74 CHEMBL
Histamine H1 receptor GPCR Ki 6.74 CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 6.66 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 6.48 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.25 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 7.34 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 8.28 CHEMBL
5-hydroxytryptamine receptor 1D GPCR ANTAGONIST IC50 5.40 IUPHAR
5-hydroxytryptamine receptor 7 GPCR Ki 6.70 SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter Transporter IC50 6.05 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel Ki 6.64 CHEMBL

External reference:

IDSource
D000078784 MESH_DESCRIPTOR_UI
D10184 KEGG_DRUG
C3667599 UMLSCUI
3O2K1S3WQV UNII
9279 INN_ID
768282000 SNOMEDCT_US
015226 NDDF
d08125 MMSL
1455099 RXNORM
4032784 VANDF
708717008 SNOMEDCT_US
9966051 PUBCHEM_CID
CHEBI:76016 CHEBI
960203-27-4 SECONDARY_CAS_RN
DB09068 DRUGBANK_ID
CHEMBL2104993 ChEMBL_ID
CHEMBL2107387 ChEMBL_ID
7351 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trintellix HUMAN PRESCRIPTION DRUG LABEL 1 55154-0256 TABLET, FILM COATED 10 mg ORAL NDA 21 sections
Trintellix HUMAN PRESCRIPTION DRUG LABEL 1 55154-0257 TABLET, FILM COATED 20 mg ORAL NDA 21 sections
Trintellix HUMAN PRESCRIPTION DRUG LABEL 1 64764-720 TABLET, FILM COATED 5 mg ORAL NDA 21 sections
Trintellix HUMAN PRESCRIPTION DRUG LABEL 1 64764-730 TABLET, FILM COATED 10 mg ORAL NDA 21 sections
Trintellix HUMAN PRESCRIPTION DRUG LABEL 1 64764-750 TABLET, FILM COATED 20 mg ORAL NDA 21 sections